ACTRN12623000382673招募中Unknown
An open-label, non-randomized, single-arm pilot study to evaluate the safety and efficacy of multiple pulsed focused ultrasound treatment in patients with drug resistant temporal lobe epilepsy
Genovate-NaviFUS (Australia) Pty Ltd0 个研究点目标入组 18 人开始时间: 2023年4月14日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Diagnosis of drug resistant temporal lobe epilepsy (TLE)
- •2.Patients must experience at least eight (8) observable seizures over the 60-day baseline, each on a separate day.
- •3.Patients have focal-onset seizures with or without secondary generalization.
- •4.Patients have had at least 24 hours video-electroencephalography (EEG) monitoring and comprehensive epilepsy evaluation confirming TLE.
- •5.Seizure medication treatment is anticipated to remain stable during the trial, except for rescue medicines or occasional extra doses of ongoing medicines, as required.
- •6.Patients should be capable of and willing to complete assessments and neuropsychological testing in English either alone or with the help of the study partner (where appropriate), per local guidelines. A study partner is a carer or family member of the patient.
- •7.Patients and study partner (if applicable) who in the Investigator’s opinion are reliable and able to use the seizure diary to record seizure throughout the study and are willing to comply with study procedures and visits.
排除标准
- •1.Patients who have primary generalized epilepsy or non-epileptic seizures in the last two (2) years.
- •2.More than two (2) seizure onset zones (foci) (except bitemporal foci) or unknown likely site of seizure onset, as determined by usual clinical, electroencephalography (EEG) and imaging practice.
- •3.Patients who have experienced tonic-clonic status epilepticus in the three (3) months leading up to enrollment in the study.
- •4.Presence of devices including but not limited to cardiac pacemaker, implantable cardioverter-defibrillator (ICD), permanent medication pumps, cochlear implants, responsive neurostimulator (RNS) or deep brain stimulation (DBS). Vagus nerve stimulators (VNS) do not represent an exclusion criterion, but settings should be stable throughout the trial.
- •5.Patients with clips or other metallic implanted objects in the FUS exposure path, except shunts.
- •6.Patients with more than thirty percent (30%) of the skull area traversed by the sonication pathway covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp at Screening.
- •7.Patients who have a medical or surgical history of severe systemic disease(s), such as (but not limited to) coronary artery disease, myocardial infarct, progressive heart failure, uncontrolled hypertension or abnormal ECG, severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg), chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, hepatic and renal insufficiency (ALT or AST 3 times above normal range; serum creatinine > 1.3 mg/dL), diabetic patients with poor control of blood sugar (HbA1c > 8.5 %) at Screening.
- •8.History of intracranial hemorrhage.
- •9.History of multiple strokes, or a stroke within the six (6) months prior to Screening.
- •10.Patients with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment at any time.
- •11.Presence of central nervous system (CNS) disease(s) other than epilepsy including but not limited to infections of the CNS (e.g., syphilis, Lyme disease, borreliosis, viral or bacterial meningitis/encephalitis, human immunodeficiency virus [HIV] encephalopathy), cerebral vascular disease, Parkinson’s disease, traumatic brain injury, alcoholic encephalopathy within three (3) years prior to Screening.
- •12.Patients with concurrent major psychiatric disorder, such as schizophrenia or bipolar disorder, severe depression, active suicidal ideation, active psychosis (excluding time-limited postictal psychosis) or psychiatric hospitalization within one (1) year before Screening.
- •13.Prior diagnosis of cancer within the past two (2) years and evidence of continued malignancy within the past two (2) years (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ prostate cancer with normal prostate-specific antigens post resection).
- •14.Patients who are not able or willing to tolerate the required prolonged stationary semi-supine position during treatment.
- •15.Inability to tolerate MRI procedures or contraindication to MRI (e.g. claustrophobia, too large for MRI scanner), including, but not limited to, presence of pacemakers (with the exception of MRI-safe pacemakers), aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or other areas of the body that would contraindicate an MRI scan.
- •16.Patients who had major surgery six (6) weeks before study enrollment or who are not fu
研究者
相似试验
进行中（未招募）
1 期
Eine offene, nicht randomisierte, einarmige Pilotstudie zur Beurteilung der Wirksamkeit von Erythropoetin bei Friedreich Ataxie.Die Friedreich Ataxie (FRDA) ist eine autosomal-rezessiv vererbte, progressive neurodegenerative Erkrankung, die mit einer Inzidenz von rund 1:50.000 auftritt. Es handelt sich dabei um die am häufigsten vorkommende Ataxie beim Menschen. Sie manifestiert sich klinisch initial als spinozerebelläre Ataxie, im weiteren Krankheitsverlauf tritt meist eine hypertrophe Kardiomyopathie hinzu, deren Komplikationen häufig für den frühen Tod der Patienten verantwortlich sind.EUCTR2005-005938-12-ATDr. Sylvia Boesch12
招募中
Unknown
Transcatheter Arterial Micro-Embolization (TAME) using Nexsphere-F in Patients with Chronic Pain in Elbow or WristDiseases of the musculoskeletal system and connective tissueKCT0009270Konkuk University Medical Center38
进行中（未招募）
1 期
A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)EUCTR2018-004451-20-DERheinische Friedrich-Wilhelms-Universität Bonn50
进行中（未招募）
不适用
Safety and Efficacy of Fluconazole 150 mg in subjects suffering from Tinea InfectionsCTRI/2020/06/026110Dr DG Saple
终止
不适用
Instylla Hydrogel Embolic System Pilot Study For Patients Requiring Transcatheter Embolization of Vascular BleedsACTRN12620000349943Instylla Inc2